For decades, Alzheimer's disease researchers have been looking for a way to predict the disease in advance that isn't incredibly invasive or expensive. Now a group of scientists at Georgetown University say they might have found it.
 
The study, published in Nature Medicine, looked at hundreds of elderly adults who were cognitively normal, trying to find a difference between those who went on to develop Alzheimer's disease or other cognitive impairment and those who didn't.
 
What they came up with was a blood test looking at 10 lipids, or fat molecules, that was able to predict who would develop the disease within two to three years with 90 percent accuracy.
 
Currently, the only tests available to predict Alzheimer's disease are either expensive, like brain scans in an MRI, or painful, like spinal taps, so few people get tested before symptoms appear. (Via Wikimedia Commons / Liz WestDocP)
 
Alzheimer's disease is a growing problem in the U.S. More than 5 million people have the disease, and that number's expected to grow to more than 7 million by 2025.
 
And while the CDC currently lists Alzheimer's disease as the sixth-leading cause of death in the U.S. with 83,000 deaths per year, a study from Rush University released last week show that number may be much higher, rivaling the half million deaths per year of cancer and heart disease.
 
And there's no cure. What's worse, the new study's lead author, Dr. Howard Federoff, says even the treatments we do have just aren't very effective.
 
"One of the reasons for this may be that the stage in which they were evaluated, which is in patients who already have the disease, may be the wrong stage." (Via Georgetown University)
 
The hope is that a simple blood test to diagnose Alzheimer's disease patients years before symptoms emerge could open the flood gates of research into new, early treatments. For that, Federoff tells CNN he considers this study the single most important finding he's ever made.
 
The new blood test still needs to be evaluated by the scientific and medical communities before it becomes widespread, which would likely take a minimum of two years.
 



About the Author

Keep Reading

Foo Fighters closed out Shaky Knees 2024 at Central Park with extended versions of their biggest hits. The indie rock festival has moved to Piedmont Park for this weekend's event. (Ryan Fleisher for the AJC)

Credit: Ryan Fleisher

Featured

In this file photo from October 2024, Atlanta Braves outfielder Jorge Soler and teammates react after losing to the San Diego Padres 5-4 in San Diego. The Braves and Soler, who now plays for the Los Angeles Angels, face a lawsuit by a fan injured at a 2021 World Series game at Truist Park in Atlanta. (Jason Getz/AJC)

Credit: Jason.Getz@ajc.com